# Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

> **NCT02174432** · PHASE2,PHASE3 · COMPLETED · sponsor: **Trevi Therapeutics** · enrollment: 36 (actual)

## Conditions studied

- Prurigo Nodularis
- Nodularis Prurigo
- Prurigo

## Interventions

- **DRUG:** nalbuphine HCl ER

## Key facts

- **NCT ID:** NCT02174432
- **Lead sponsor:** Trevi Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-15
- **Primary completion:** 2017-09-03
- **Final completion:** 2017-09-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02174432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02174432, "Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02174432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*